Cell and Gene Therapies in Rare Disorders Market Outlook, Trends And Future Opportunities (2024-2031)

Cell and Gene Therapies in Rare Disorders Market, By Type of Therapy (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), By Disease Indication (Neurological Disorders, Hematological Disorders, Metabolic Disorders, Ophthalmological Disorders, Immunological Disorders, Musculoskeletal Disorders, Others), By Vector Type (Viral Vectors, Non-Viral Vectors), By Cell Type (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Others), By Route of Administration (Intravenous, Intramuscular, Subretinal, Others), By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

Published On: Mar 2024
Author(s): Sagar Karlekar
Report ID: IDA65
Region: Global
Format: PDF/EXCEL

Press Release: Cell and Gene Therapies in Rare Disorders Market is Forecasted to Hit US$ 17.3 Bn By 2031 | CAGR 25.6%

Table Of Contents:

Chapter 1. Research Methodology and Scope

- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology

Chapter 2. Executive Summary

- Market Landscape
- Market Size & Forecast
- Competitive Landscape

Chapter 3. Cell and Gene Therapies in Rare Disorders Market: By Type of Therapy Market Trends, Size, and Future Outlook

- By Type of Therapy Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Type of Therapy Definitions, Technology Landscape
- By Type of Therapy Market Drivers
  - Product Launches
  - Technology Launches
- By Type of Therapy Market Restraints

Chapter 4. Cell and Gene Therapies in Rare Disorders Market: By Disease Indication Market Trends, Size, and Future Outlook

- By Disease Indication Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Disease Indication Definitions, Technology Landscape
- By Disease Indication Market Drivers
  - Product Launches
  - Technology Launches
- By Disease Indication Market Restraints

Chapter 5. Cell and Gene Therapies in Rare Disorders Market: By Vector Type Market Trends, Size, and Future Outlook

- By Vector Type Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Vector Type Definitions, Technology Landscape
- By Vector Type Market Drivers
  - Product Launches
  - Technology Launches
- By Vector Type Market Restraints

Chapter 6. Cell and Gene Therapies in Rare Disorders Market: By Cell Type Market Trends, Size, and Future Outlook

- By Cell Type Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Cell Type Definitions, Technology Landscape
- By Cell Type Market Drivers
  - Product Launches
  - Technology Launches
- By Cell Type Market Restraints

Chapter 7. Cell and Gene Therapies in Rare Disorders Market: By Route of Administration Market Trends, Size, and Future Outlook

- By Route of Administration Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Route of Administration Definitions, Technology Landscape
- By Route of Administration Market Drivers
  - Product Launches
  - Technology Launches
- By Route of Administration Market

Chapter 8. Cell and Gene Therapies in Rare Disorders Market: By End-User Market Trends, Size, and Future Outlook

- By End-User Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By End-User Definitions, Technology Landscape
- By End-User Market Drivers
  - Product Launches
  - Technology Launches
- By End-User Market Restraints

Chapter 9. Cell and Gene Therapies in Rare Disorders Market: Regional Market Trends, Size, and Future Outlook

- North America
  - Market Size (US$), CAGR (%), and Future Outlook
  - Market Size (US$), CAGR (%), and Forecast (2023-2031)
  - Market Drivers and Restraints
- Europe
  - Market Size (US$), CAGR (%), and Future Outlook
  - Market Size (US$), CAGR (%), and Forecast (2023-2031)
  - Market Drivers and Restraints
- Asia Pacific
  - Market Size (US$), CAGR (%), and Future Outlook
  - Market Size (US$), CAGR (%), and Forecast (2023-2031)
  - Market Drivers and Restraints
- Latin America
  - Market Size (US$), CAGR (%), and Future Outlook
  - Market Size (US$), CAGR (%), and Forecast (2023-2031)
  - Market Drivers and Restraints
- Middle East & Africa
  - Market Size (US$), CAGR (%), and Future Outlook
  - Market Size (US$), CAGR (%), and Forecast (2023-2031)
  - Market Drivers and Restraints

Chapter 10. Cell and Gene Therapies in Rare Disorders Market: Competitive Landscape

- Novartis AG
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Gilead Sciences, Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Bluebird Bio, Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Spark Therapeutics, Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Amgen Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Sanofi
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- UniQure N.V.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Orchard Therapeutics plc
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Biogen Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- REGENXBIO Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Solid Biosciences Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- GlaxoSmithKline plc
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Allergan plc
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- BioMarin Pharmaceutical Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Shire plc (Takeda Pharmaceutical Company Limited)
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Sangamo Therapeutics, Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Editas Medicine, Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- CRISPR Therapeutics AG
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies
- Intellia Therapeutics, Inc.
  - Company Overview
  - Financial Outlook
  - Product Portfolio
  - Strategies

Research Methodology

- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases

Appendix

- About Us

Frequently Asked Questions

The current market size of the Cell and Gene Therapies in Rare Disorders industry is USD 2.8 billion as of 2023.

The increasing prevalence of rare disorders, lack of effective treatment options, technological advancements in cell and gene therapies, rising investments in R&D activities, personalized medicine approach, and gene-editing technologies like CRISPR are contributing significantly to the growth of the Cell and Gene Therapies in Rare Disorders market.

The high costs of cell and gene therapies, regulatory and ethical concerns, challenges in manufacturing and scaling up, and limited understanding of disease mechanisms are the key factors hampering the growth of the Cell and Gene Therapies in Rare Disorders Market.

The gene therapy segment is the leading component segment in the Cell and Gene Therapies in Rare Disorders Market, providing innovative treatments for various rare genetic disorders.

Novartis AG, Gilead Sciences, Inc., Bluebird Bio, Inc., Spark Therapeutics, Inc., Amgen Inc., Sanofi, UniQure N.V., Orchard Therapeutics plc, Biogen Inc., and REGENXBIO Inc. are among the major players operating in the Cell and Gene Therapies in Rare Disorders Market.

The North America region is expected to lead the Cell and Gene Therapies in Rare Disorders Market, with a market size of USD 17.3 billion by 2031, growing at a CAGR of 25.6% from 2023 to 2031.

The increasing prevalence of rare disorders, lack of effective treatment options, technological advancements in cell and gene therapies, rising investments in R&D activities, personalized medicine approach, gene-editing technologies like CRISPR, and growing awareness about rare diseases are the key drivers of the Cell and Gene Therapies in Rare Disorders Market.

Download FREE Sample Buy Now

Cell and Gene Therapies in Rare Disorders Market Outlook, Trends And Future Opportunities (2024-2031)

Cell and Gene Therapies in Rare Disorders Market Outlook, Trends And Future Opportunities (2024-2031)

Frequently Asked Questions

BUYING OPTIONS

Useful Links

Cell and Gene Therapies in Rare Disorders Market Outlook, Trends And Future Opportunities (2024-2031)

Cell and Gene Therapies in Rare Disorders Market Outlook, Trends And Future Opportunities (2024-2031)

Frequently Asked Questions

What is the current market size of the Cell and Gene Therapies in Rare Disorders industry?

What factors are contributing significantly to the growth of the Cell and Gene Therapies in Rare Disorders market?

What are the key factors hampering the growth of the Cell and Gene Therapies in Rare Disorders Market?

Which is the leading component segment in the Cell and Gene Therapies in Rare Disorders Market?

Which are the major players operating in the Cell and Gene Therapies in Rare Disorders Market?

What will be the CAGR and market size of the Cell and Gene Therapies in Rare Disorders Market?

What are the drivers of the Cell and Gene Therapies in Rare Disorders Market?

BUYING OPTIONS